Repair and pain
Will it help my knees?
One of the two things people most often report trying peptides for, and one of the thinnest human evidence bases on this site.
796
people in trials
3
human studies
2
compounds, animal or cell only
1
trials found nothing
Measured in people
Ranked by how many people, which is a fact about the evidence and not a judgement about the compound. The one at the top is the most studied, which is not the same as the best. Counts are never added across compounds, because the same person can appear in more than one trial.
- 538 people1 human study
Whole purified venom, not melittin. 538 patients with knee osteoarthritis randomised 1:2 to histamine control or 100 mcg venom in 15 dermal injections at acupuncture points weekly for 12 weeks. WOMAC pain improved 1.1 points more than control (95% CI 0.3 to 2.0, p = 0.001) and physical function 3.1 points (p = 0.0046). Injection site reactions under 5 percent. Described as a phase 3; funding not stated in the abstract.
Journal of Alternative and Complementary Medicine, 2019 · 538 people
What people using it report
- Bee venom therapy, using live stings or injected venom, has a long lay tradition for arthritis, multiple sclerosis and chronic pain; the 2005 MS trial was run because patients were already doing it, and the Parkinson trial used a standard allergy desensitisation dosing scheme for the same reason.
- 183 people1 human study
Unity Biotechnology, phase 2, randomised, triple masked, 183 participants (placebo 46, UBX0101 0.5 mg 45, 2.0 mg 46, 4.0 mg 46). Results posted December 2021. WOMAC pain subscale fell from about 2.1 at baseline to 1.12 on placebo versus 1.16, 1.04 and 1.10 on the three doses at week 12. Function and daily pain scores likewise showed no separation. Serious adverse events 1, 2, 1 and 3 by arm; one death recorded in the 4.0 mg arm, cause not given in the posting.
ClinicalTrials.gov, 2026 · 183 people
Also measured, in animals or cells
Mouse. Using the p16-3MR transgenic model after anterior cruciate ligament transection, selective elimination of senescent cells attenuated post-traumatic osteoarthritis, reduced pain and increased cartilage development, reproduced by intra-articular injection of a senolytic molecule in transgenic, non-transgenic and aged mice. Cells from patients undergoing knee replacement were treated in culture, not in the patients.
Nature Medicine, 2017 · animal
- 75 people1 human study1 found nothing
found nothingDouble-blinded randomised controlled trial at a single centre, enrolling June 2018 to May 2019. 75 people with symptomatic Kellgren-Lawrence grade 2 or 3 knee osteoarthritis randomised to intra-articular A2M-rich concentrate, conventional platelet-rich plasma, or methylprednisolone, followed 12 weeks; 68 (90.7 percent) completed, 73 percent female, mean age 59. At 12 weeks the A2M group improved significantly on visual analogue scale, WOMAC, KOOS and Tegner; the platelet-rich plasma group improved on nothing; the steroid group improved on Lysholm only. Between-group changes did not differ significantly. The authors concluded A2M is not superior and, given higher preparation cost, may not be justifiable for routine treatment.
Bulletin of the Hospital for Joint Diseases, 2024 · 75 people
Also measured, in animals or cells
Minipig. A2M reduced post-traumatic osteoarthritis cartilage damage by inhibiting inflammatory pathways, in a model combining joint injury with modified intra-articular drilling.
What people using it report
- A2M injections are offered in orthopaedic and regenerative medicine practice for knee and other joint osteoarthritis, prepared by concentrating the protein from a sample of the patient's own blood at the point of care. The marketed rationale is inhibition of cartilage-degrading enzymes.
- The trial that tested this use documents what the procedure involves and who receives it: people with radiographically confirmed Kellgren-Lawrence grade 2 or 3 knee osteoarthritis, mean age 59, mostly women, given a single intra-articular injection.
Measured in animals or cells, not yet in people
These are separated from the trials above rather than ranked against them, because they answer a different question. A result in a rat is a real result and a reason somebody ran the study; it is not a measurement of what happens in you. Where the human work is missing, the reason is usually money rather than failure, and that is set out at the bottom of this page.
- 1 preclinical study
Measured in animals or cells
Rat osteoarthritis model, with supporting experiments in meniscus cells and chondrocytes from patients with osteoarthritis. Piperlongumine reduced p16 and p21 and senescence-associated secretory factors and slowed disease progression in the rats. The human component is cells in a dish, not treated patients.
Biochemical and Biophysical Research Communications, 2026 · animal
- 1 preclinical study
Measured in animals or cells
Cell culture. The senescence-associated secretory phenotype of chondrocytes was characterised by raised p16, p21 and p53, raised TNF-alpha and IL-1-alpha, and lowered Sirt1. Both the AED peptide and a cartilage polypeptide complex normalised the synthesis of those molecules. Chondrocytes in culture, not joints, and no clinical endpoint was measured.
Advances in Gerontology, 2023 · in vitro
What people using these actually report
Uncontrolled self-reports, gathered from clinic write-ups, regulatory complaint records and public forums, and reproduced here as written. They are the best guide on this page to what people actually do, what they expect, and what goes wrong, and they cannot show that anything works, because nobody was measured against a placebo and the people who saw no effect mostly stopped posting. Both halves of that are true at once. The negative reports are kept in for the same reason.
- Bee venom therapy, using live stings or injected venom, has a long lay tradition for arthritis, multiple sclerosis and chronic pain; the 2005 MS trial was run because patients were already doing it, and the Parkinson trial used a standard allergy desensitisation dosing scheme for the same reason.
Sources: The published apitherapy and bee venom acupuncture literature, including the Toxicon 2018 review, the Korean safety trial of filtered versus unfiltered venom, the recruitment rationale stated in the MS and Parkinson trials, and the registered Apitox trials. No forum or social media content was retrieved for this entry and nothing here is attributed to a specific post.
- A2M injections are offered in orthopaedic and regenerative medicine practice for knee and other joint osteoarthritis, prepared by concentrating the protein from a sample of the patient's own blood at the point of care. The marketed rationale is inhibition of cartilage-degrading enzymes.
- The trial that tested this use documents what the procedure involves and who receives it: people with radiographically confirmed Kellgren-Lawrence grade 2 or 3 knee osteoarthritis, mean age 59, mostly women, given a single intra-articular injection.
Sources: The published randomised controlled trial in the Bulletin of the Hospital for Joint Diseases 2024, which is the source for the procedure description, the population treated, the comparators and the cost conclusion; the 2015 PLoS One naked mole rat comparative study, which is the source of the longevity rationale that appears in marketing. No clinic website, forum post or individual patient account is quoted or relied on here.
- The injuries people describe treating are tendinopathy, especially elbow, shoulder and Achilles, partial muscle tears, knee pain and post-surgical recovery, plus gut complaints such as reflux and inflammatory bowel symptoms.
Sources: FDA's July 2026 evaluation of BPC-157, which reproduces the FAERS adverse event reports through December 4, 2025, the Human Foods Program complaint records, and the marketed dosage forms and strengths; the three published clinic reports above, which are the only documented clinical practice; the 2025 HSS Journal systematic review and the 2026 American Journal of Sports Medicine and Sports Medicine reviews, which describe how athletes and clinicians are using these peptides and note that indications, dosing, frequency and duration all remain undefined; and public injury logs and question threads on peptide and bodybuilding forums including eroids, iSARMS, Ironsport and FITMISC. Reddit's r/Peptides and r/PeptideSupport could not be retrieved for this entry, so nothing above is attributed to any specific post, and no quotation is reproduced from any of these sources.
- Nagging tendon or joint pain easing, described in the same terms used for BPC-157 alone.
Sources: Peptide and skincare forums including r/peptides, clinic write-ups and vendor testimonial pages. No trial of this blend exists, so none of this comes from trial exit interviews or an adverse event table for the product. Most people posting are using a topical copper product at the same time as the injection, which makes attribution impossible even within the report. The FDA adverse event material comes from the agency's 2026 BPC-157 evaluation cited on this page.
- Reduced tendon and joint pain in the first few weeks, described the same way people describe BPC-157 alone.
Sources: Peptide forums including r/peptides, vendor product pages and price-comparison listings. Uncontrolled self-reports from people usually running other compounds at the same time. Recorded as reports, not evidence.
- Tendon and joint pain improving over two to six weeks.
Sources: Peptide forums including r/peptides, clinic write-ups and vendor pages. Uncontrolled self-reports. The sting comparison in particular is unblinded and the two products look different in the vial.
- Joint pain improving, which is the effect BPC-157 users report on its own.
Sources: Forums including r/peptides and r/Semaglutide, and clinic write-ups. Uncontrolled self-reports with a large confound: GLP-1 nausea reliably fades over the first weeks whether or not anything is added.
Why the trial record looks like this
A missing trial is usually a missing sponsor. Nobody runs a nine-figure programme on a molecule they cannot own, so the compounds with the thinnest human records are often the oldest and most freely available ones rather than the weakest. Taking Piperlongumine as the example, because it states the problem most clearly:
Piperlongumine is a plant alkaloid, which means no one can own it, which means no sponsor has a commercial reason to pay for the trials that would settle what it does in people. That is an economic fact about the compound rather than a scientific verdict on it. The reverse holds with equal force: without trials, neither harm nor uselessness would be detected, and the reactive lactam chemistry that drives the senolytic effect is the kind of chemistry that usually warrants human safety data before use.
Its senolytic literature is small, recent, and dominated by the group that discovered it. The osteoarthritis result is a single rat study published in 2026 and has not been replicated.
A compound appears here only when a citation on its own page states this outcome and reports a result for it; naming it is not enough. Human, animal and cell work are counted separately and never merged. Participant counts are read from the study lines and deliberately undercount. Nothing here is advice, and nothing here is a recommendation to take or to avoid anything.